The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function

Bone Marrow Transplantation

Volumn 26, Issue 2, 2000, Pages 133-139

  Rose, M ^a   Lee, F A ^a   Gollerkeri, A ^a   D'Andrea, E ^b   Psyrri, A ^a   Bdolah Abram, T ^c   Burtness, B A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Breast neoplasm; Cardiomyopathy; Stem cells

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ARTICLE; BREAST CANCER; CARDIOTOXICITY; CELL MOTILITY; FEASIBILITY STUDY; FEMALE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCINTIANGIOGRAPHY; STEM CELL TRANSPLANTATION;

EID: 0033915466     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702449     Document Type: Article

References (27)

1. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
2. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med 1999; 339: 900-905.
3. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
4. Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Engl J Med 1991; 324: 808-815.
5. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Ped Oncology 1995; 24: 352-361.
6. Fraiser LH, Kanekal S, Kehrer J. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 1991; 42: 781-795.
7. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
8. Braverman AC, Antin JH, Plapert MT et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-1223.
9. Lee C-K, Harman GS, Hohl RJ, Gingrich RD. Fatal cyclophosphamide cardiomyopathy; its clinical course and treatment. Bone Marrow Transplant 1996; 18: 573-577.
10. Goldberg MA, Antin JH, Guinan EC et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114-1118.
11. Rowinsky EK, McGuire WP, Guarnieri T et al. Cardiac disturbances during the administration of Taxol. J Clin Oncol 1991; 9: 1704-1712.
12. Garcia-Carbonero R, Hidalgo M, Paz-Ares L et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 1997; 15: 3178-3184.
13. Burtness BA, Psyrri A, Rose M et al. A phase I study of paclitaxel for mobilization of stem cells. Bone Marrow Transplant 1999; 23: 311-315.
14. Lee FA, Fetterman R, Zaret BL, Wackers FJTh. Rapid radionuclide-derived systolic and diastolic cardiac function using cycle-dependent background correction and Fourier analysis. Computers Cardiol 1986; 443-446.
15. van Royen N, Jaffe CC, Krumholz HM et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 1996; 77: 843-850.
16. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89; 2233-2258.
17. Basser RL, Abraham R, Bik To L et al. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer. Ann Oncol 1999; 10: 53-58.
18. de Graaf H, Dolsma WV, Willemse PHB et al. Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. Br J Cancer 1997; 76: 943-945.
19. Carlson K, Smedmyr B, Backlund L, Simonsson B. Subclinical disturbances in cardiac function at rest and in gas exchange during exercise are common findings after autologous bone marrow transplant. Bone Marrow Transplant 1994; 14: 949-954.
20. Kakavas PW, Ghalie R, Parrillo JE et al. Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Bone Marrow Transplant 1995; 15: 859-861.
21. Ghielmini M, Zappa F, Menafoglio A et al. The high-dose sequential (Milan) chemotherapy/PBSC transplantation regimen for patients with lymphoma is not cardiotoxic. Ann Oncol 1999; 10: 533-537.
22. Shek TW, Luk IS, Ma L et al. Paclitaxel-induced cardiotoxicity. An ultrastructural study. Arch Pathol Lab Med 1996; 120: 89-91.
23. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-2699.
24. Sparano JA. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol 1998; 25 (4 Suppl. 10): 66-71.
25. Alexander J, Dainiak N, Berger HJ et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. New Engl J Med 1979; 300: 278-283.
26. Schwartz, RG, McKenzie WB, Alexander J et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109-1118.
27. Ganz WI, Sridhar KS, Ganz SS et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461-470.